Neurocrine Biosciences | NBIX - Loan Capital


Neurocrine Biosciences reported $169.5M in Loan Capital for its fiscal quarter ending in March of 2023.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
ALKERMES USD 285.82M 639K Sep/2024
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Amgen USD 50B 2.43B Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Cytokinetics USD 1.12B 957.23M Dec/2025
Enanta Pharmaceuticals USD 0 0 Dec/2024
Gilead Sciences USD 22.14B 5M Sep/2025
Halozyme Therapeutics USD 2.14B 1.34B Dec/2025
Incyte USD 30.2M 5.17M Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Nektar Therapeutics USD 107.51M 10.35M Jun/2024
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pfizer USD 57.41B 93M Sep/2025
Prothena USD 0 0 Dec/2024
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Repligen USD 542.21M 4.29M Dec/2025
Rigel Pharmaceuticals USD 0 0 Sep/2024
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Teva Pharmaceutical Industries USD 14.99B 1.78B Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025
Xoma USD 94.38M 7.82M Sep/2025